The content on this site is intended for healthcare professionals only
Dr Criscitiello speaks at EONS 10, presenting results from clinical trials of CDK4/6 inhibitors palbociclib, ribociclib and abemaciclib.
CDKs were also discussed at an ecancer symposium at ESMO 2016.
Supported by a grant from Pfizer Inc.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Advancements in paediatric Acute lymphoblastic leukemia management
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours
EAU 2024: Bladder cancer latest
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Breast Cancer
Overview of the management of HER2-low breast cancer patients
